Company profile: BioArctic
1.1 - Company Overview
Company description
- Provider of research-oriented biopharma solutions focused on neurodegenerative diseases, including Lecanemab—an antibody targeting amyloid-beta oligomers and protofibrils for Alzheimer’s—R&D of treatments addressing the cause of nerve cell damage in Parkinson’s disease and ALS, and brain transporter technology to enable drug delivery across the blood-brain barrier.
Products and services
- Lecanemab: Antibody-based therapy targeting amyloid-beta oligomers and protofibrils, intercepting harmful aggregates in Alzheimer’s disease and engineered to neutralize pathogenic assemblies
- Brain Transporter Technology: Platform-level drug-delivery technology enabling passage across the blood-brain barrier, constructed to enhance delivery of therapeutics into the brain
- Parkinson’s Disease Treatment: Mechanism-focused R&D targeting the cause of nerve cell damage in Parkinson’s disease, developed to address underlying neurodegeneration
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to BioArctic
Mivi Neuroscience
HQ: United States
Website
- Description: Provider of clinical solutions for neurointerventional procedures, including the DAISe Thrombectomy System to assist clot retrieval and reduce distal embolization; the Q Aspiration Catheter for clot removal in neurovascular systems with increased flow rates; the Q Distal Access Catheter for guiding microcatheters into blood vessels; and MIVI High Flow Tubing HFT 110 used with aspiration pumps and catheters for removing body fluids.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Mivi Neuroscience company profile →
Achieve Life Sciences
HQ: United States
Website
- Description: Provider of specialty pharmaceutical products, manufacturing and developing cytisinicline, a plant-based alkaloid for nicotine addiction, including smoking and e-cigarette cessation, that interacts with nicotine receptors to reduce withdrawal symptoms and the reward associated with nicotine products.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Achieve Life Sciences company profile →
Emalex Biosciences
HQ: United States
Website
- Description: Provider of biotech therapies for central nervous system disorders, developing Ecopipam, a novel investigational D1 receptor dopamine blocker targeting Tourette syndrome, and conducting an FDA-regulated Phase 3 trial (EBS-101) in children, adolescents, and adults with Tourette’s. Also pursuing investigational treatments for childhood-onset fluency disorder (stuttering) in adults.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Emalex Biosciences company profile →
Aeon Biopharma
HQ: United States
Website
- Description: Provider of biopharmaceutical therapies, developing novel and proprietary treatment paradigms to improve patient outcomes.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Aeon Biopharma company profile →
NextWave Pharma
HQ: United States
Website
- Description: Provider of pharmaceutical products developed and commercialized using proprietary drug delivery technology; based in Cupertino, CA.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full NextWave Pharma company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for BioArctic
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to BioArctic
2.2 - Growth funds investing in similar companies to BioArctic
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for BioArctic
4.2 - Public trading comparable groups for BioArctic
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →